Thermo Fisher Scientific Acquires Olink Holding AB

Thermo Fisher Scientific Acquires The Binding Site Group

October 31, 2022

Medical Devices

Thermo Fisher Scientific has entered into a definitive agreement to acquire The Binding Site Group from a shareholder group led by Nordic Capital for £2.25 billion (about $2.6 billion). The Binding Site, a Birmingham-based specialist in protein and blood-cancer diagnostics with more than 1,100 employees and ~10% annual revenue growth, will join Thermo Fisher's Specialty Diagnostics segment to expand its capabilities in cancer diagnostics and monitoring.

Thermo Fisher Scientific to Acquire Clario Holdings for $8.875 Billion

October 29, 2025

Healthcare Services

Thermo Fisher Scientific has announced an agreement to buy Clario Holdings, a provider of digital endpoint data solutions for clinical trials, for $8.875 billion in cash plus up to $400 million in earnout payments. The acquisition is expected to close by mid-2026, subject to regulatory approvals, and will expand Thermo Fisher’s digital capabilities for pharma and biotech clinical research.

Olink Proteomics Acquires Agrisera AB

May 12, 2020

Biotechnology

Olink Proteomics AB has acquired Agrisera AB, a Swedish antibody producer, to accelerate development and in‑house production of antibodies for Olink’s PEA immunoassay portfolio. The deal secures supply, lowers cost for customers, and expands Olink’s assay development capabilities by integrating Agrisera’s high-throughput antibody production.

Thermo Fisher Scientific Completes Acquisition of PPD, Inc.

December 8, 2021

Healthcare Services

Thermo Fisher Scientific completed its acquisition of PPD, Inc., a leading global provider of clinical research services, for $17.4 billion. The deal extends Thermo Fisher’s clinical research capabilities across the drug development spectrum and is expected to generate total synergies of approximately $125 million by year three following close.

PerkinElmer Acquires BioLegend for Approximately $5.25 Billion

July 26, 2021

Biotechnology

PerkinElmer, Inc. agreed to acquire BioLegend, a leading developer of antibodies and life-science reagents, for approximately $5.25 billion in cash and stock. The acquisition expands PerkinElmer's life-science franchise into high-growth areas such as biologics, cell and gene therapy, and proteogenomics, and is expected to be accretive to earnings.

Thermo Fisher Scientific Acquires Solventum's Purification & Filtration Business

September 2, 2025

Manufacturing

Thermo Fisher Scientific completed the acquisition of Solventum's Purification & Filtration business for approximately $4.0 billion in cash. The divested business—now Thermo Fisher's Filtration and Separation business—adds bioprocessing filtration, industrial filtration and membrane technologies to Thermo Fisher's Life Sciences Solutions portfolio and is expected to generate about $750 million in revenue in 2025.